This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Goldman Sachs Keeps Their Sell Rating on Dynavax (DVAX)
Goldman Sachs analyst Paul Choi reiterated a Sell rating on Dynavax today and set a price target of $11.00. The company’s shares closed today at $10.95.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Choi covers the Healthcare sector, focusing on stocks such as Lantheus, RegenXBio, and Urogen Pharma. According to TipRanks, Choi has an average return of 7.8% and a 54.78% success rate on recommended stocks.
Currently, the analyst consensus on Dynavax is a Moderate Buy with an average price target of $19.63.
DVAX market cap is currently $1.23B and has a P/E ratio of -21.96.
Read More on DVAX:
Disclaimer & DisclosureReport an Issue
- Buy Rating for Dynavax Driven by Promising Z-1018 Vaccine Developments and Heplisav Revenue Growth
- Dynavax Announces Positive Results for Shingles Vaccine
- Dynavax’s Z-1018 shingles vaccine shows efficacy in Phase 1/2 trial
- Dynavax Technologies Reports Strong Q2 Earnings
- Dynavax price target raised to $32 from $31 at Citizens JMP
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
